Munich - Delayed Quote EUR

MediPharm Labs Corp (MLZ.MU)

0.0497
+0.0033
+(7.11%)
At close: June 6 at 9:55:00 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for MLZ.MU

Recent News: MLZ.MU

View More
MediPharm Labs Closes $4.5 Million Sale of Hope, BC Facility and Announces Plans to Expand EU GMP Cultivation Capacity at Napanee Facility

MediPharm Labs Closes $4.5 Million Sale of Hope, BC Facility and Announces Plans to Expand EU GMP Cultivation Capacity at Napanee Facility
GlobeNewswire 3 days ago
Apollo Capital Warns MediPharm Shareholders Current CEO David Pidduck is Looking for an Exit

Apollo Capital Warns MediPharm Shareholders Current CEO David Pidduck is Looking for an Exit
GlobeNewswire 5 days ago
Leading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees; REJECTS Apollo’s Arguments and Director Slate

Leading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees; REJECTS Apollo’s Arguments and Director Slate
GlobeNewswire 6 days ago
MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital

MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital
GlobeNewswire 9 days ago
Apollo Capital alleges securities fraud at Medipharm Labs

Apollo Capital alleges securities fraud at Medipharm Labs
TipRanks 9 days ago
MediPharm Labs Responds to Fabricated Allegations from Dissident Shareholder

MediPharm Labs Responds to Fabricated Allegations from Dissident Shareholder
GlobeNewswire 10 days ago
Alleged Securities Fraud at MediPharm Labs Says Apollo Capital

Alleged Securities Fraud at MediPharm Labs Says Apollo Capital
GlobeNewswire 10 days ago
MediPharm Labs Board Issues Letter to Shareholders in Response to Inadequate Dissident Plan

MediPharm Labs Board Issues Letter to Shareholders in Response to Inadequate Dissident Plan
GlobeNewswire 11 days ago
Apollo Capital Calls Out MediPharm Chairman Chris Taves (Managing Director, BMO Capital Markets) for Failure to Properly Communicate to Shareholders Details of David Pidduck’s Past as CEO and VP of Marketing for OxyContin® Manufacturer Purdue Pharma

Apollo Capital Calls Out MediPharm Chairman Chris Taves (Managing Director, BMO Capital Markets) for Failure to Properly Communicate to Shareholders Details of David Pidduck’s Past as CEO and VP of Marketing for OxyContin® Manufacturer Purdue Pharma
GlobeNewswire 12 days ago
MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution Agreement

MediPharm Labs Begins Production of First Order for International Expansion of Novel Cannabis Metered Dose Portfolio in the EU and United Kingdom Under Blackpoint Sales and Distribution Agreement
GlobeNewswire 13 days ago
MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd.

MediPharm Labs Cautions Shareholders about Dissident Nominees’ Governance Failures at Check-Cap Ltd.
GlobeNewswire 16 days ago
View More

Related Tickers

0OG.MU Organigram Global Inc. R
1.1300
-3.42%
 
76U0.DU Verano Holdings Corp
0.4100
-8.48%
 
R9U2.DU Green Thumb Industries Inc
4.5180
+0.44%
 
R9U2.BE Green Thumb Industries Inc
4.5900
+0.61%
 
21P.HM Aurora Cannabis Inc
4.9050
+1.13%
 
Y230.SG Akanda Corp.
1.1500
+2.68%
 
R9U2.SG Green Thumb Industries Inc
4.4300
+0.05%
 
Y7Q.MU Planet 13 Holdings Inc. R
0.1920
-1.54%
 
21P.BE Aurora Cannabis Inc. R
4.7000
-2.49%
 
T0A.F Trulieve Cannabis Corp.
3.4200
+3.20%